Evgen Pharma (EVG) RNS Announcements

Add to Alert list
Date Time Source Announcement
27 Feb 2024 07:00 AM
RNS
SFX-01 positive update in bowel cancer models
19 Feb 2024 11:22 AM
RNS
Positive update on SFX-01 in vitro GBM studies
09 Feb 2024 11:01 AM
RNS
Notice of Dispute lodged with Stalicla SA
16 Jan 2024 03:07 PM
RNS
Series B Fund Raise by partner, Stalicla SA
29 Dec 2023 11:29 AM
RNS
Holding(s) in Company
22 Dec 2023 07:00 AM
RNS
Directorate Changes
13 Nov 2023 07:00 AM
RNS
Upcoming conferences
31 Oct 2023 07:00 AM
RNS
Half-year Report
26 Oct 2023 07:00 AM
RNS
Erasmus Medical Center begins glioblastoma studies
19 Oct 2023 02:26 PM
RNS
Authored Article Publication
05 Sep 2023 07:00 AM
RNS
Directorate Changes
15 Aug 2023 07:00 AM
RNS
Final Report from Phase 1b PK/PD study
03 Aug 2023 12:38 PM
RNS
Rule 17 Disclosure
02 Aug 2023 07:00 AM
RNS
Return of rights to Sulforadex from Juvenescence
21 Jul 2023 12:02 PM
RNS
Result of AGM
27 Jun 2023 07:00 AM
RNS
SFX-01 radiosensitisation effect confirmed in-vivo
20 Jun 2023 01:59 PM
RNS
Notice of AGM & Posting of Annual Report
19 Jun 2023 07:00 AM
RNS
Grant Success for Glioblastoma studies
07 Jun 2023 07:00 AM
RNS
Final Results
26 May 2023 11:00 AM
RNS
Notice of Results
01 May 2023 07:59 PM
BZW
Distribution Dates and Amounts Announced for ...
22 Mar 2023 07:00 AM
RNS
Preliminary results from Phase 1b study
16 Mar 2023 02:00 PM
RNS
Price Monitoring Extension
16 Mar 2023 11:05 AM
RNS
Second Price Monitoring Extn
16 Mar 2023 11:00 AM
RNS
Price Monitoring Extension
16 Mar 2023 07:00 AM
RNS
Further evidence of radiosensitisation by SFX-01
13 Mar 2023 07:00 AM
RNS
No exposure to Silicon Valley Bank
25 Jan 2023 07:00 AM
RNS
Clinical trial update
14 Dec 2022 05:08 PM
RNS
Grant of Options - Director/PDMR Shareholding
12 Dec 2022 11:53 AM
EQS
Evgen Pharma 'cash runway in pretty good shape'
08 Dec 2022 07:00 AM
RNS
Half-year Report
02 Dec 2022 07:00 AM
RNS
Notice of Half Year Results
30 Nov 2022 02:06 PM
RNS
Second Price Monitoring Extn
30 Nov 2022 02:00 PM
RNS
Price Monitoring Extension
16 Nov 2022 07:00 AM
RNS
Study started of new SFX-01 tablet formulation
21 Oct 2022 11:05 AM
RNS
Second Price Monitoring Extn
21 Oct 2022 11:00 AM
RNS
Price Monitoring Extension
12 Oct 2022 04:41 PM
RNS
Second Price Monitoring Extn
12 Oct 2022 04:35 PM
RNS
Price Monitoring Extension
12 Oct 2022 07:00 AM
RNS
Clinical trial update
10 Oct 2022 11:05 AM
RNS
Second Price Monitoring Extn
10 Oct 2022 11:00 AM
RNS
Price Monitoring Extension
10 Oct 2022 07:00 AM
RNS
SFX-01 licensing deal for up to $160.5m
29 Sep 2022 07:00 AM
RNS
Regulatory approval for healthy volunteer study
22 Jul 2022 07:00 AM
RNS
Result of AGM
14 Jul 2022 12:43 PM
RNS
Investor Presentation
06 Jul 2022 12:25 PM
RNS
Notice of AGM
13 Jun 2022 07:00 AM
RNS
Collaboration with University of Michigan
08 Jun 2022 07:00 AM
RNS
Full Year Results
07 Jun 2022 07:00 AM
RNS
Notice of Results
UK 100

Latest directors dealings